BB Biotech’s Vertex Pharmaceuticals VRTX Stock Holding History

BB Biotech’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$239M	Sell	1,300,000 -70,445	-5%	-$13M	6.01%	4
2018 Q4	$227M	Hold	1,370,445	–	–	7.28%	4
2018 Q3	$264M	Sell	1,370,445 -30,000	-2%	-$5.34M	6.99%	4
2018 Q2	$238M	Sell	1,400,445 -75,000	-5%	-$11.6M	6.87%	5
2018 Q1	$240M	Hold	1,475,445	–	–	6.65%	5
2017 Q4	$221M	Hold	1,475,445	–	–	6.23%	5
2017 Q3	$224M	Hold	1,475,445	–	–	6.21%	5
2017 Q2	$190M	Buy	1,475,445 +20,000	+1%	+$2.41M	5.81%	6
2017 Q1	$159M	Buy	1,455,445 +40,000	+3%	+$3.52M	5.21%	7
2016 Q4	$104M	Hold	1,415,445	–	–	3.86%	10
2016 Q3	$123M	Hold	1,415,445	–	–	4.34%	9
2016 Q2	$122M	Buy	1,415,445 +50,000	+4%	+$4.32M	4.81%	8
2016 Q1	$109M	Hold	1,365,445	–	–	4.31%	9
2015 Q4	$172M	Hold	1,365,445	–	–	4.84%	8
2015 Q3	$142M	Buy	1,365,445 +31,000	+2%	+$3.98M	4.51%	8
2015 Q2	$165M	Hold	1,334,445	–	–	4.47%	7
2015 Q1	$157M	Sell	1,334,445 -20,000	-1%	-$2.4M	4.69%	7
2014 Q4	$161M	Hold	1,354,445	–	–	5.21%	6
2014 Q3	$152M	Sell	1,354,445 -50,000	-4%	-$4.76M	6.19%	5
2014 Q2	$133M	Hold	1,404,445	–	–	6.32%	5
2014 Q1	$99.3M	Hold	1,404,445	–	–	5.12%	6
2013 Q4	$104M	Hold	1,404,445	–	–	5.58%	5
2013 Q3	$106M	Hold	1,404,445	–	–	5.79%	5
2013 Q2	$112M	Buy	+1,404,445	New	+$103M	8.1%	5

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BB Biotech's VRTX Position: Q1 2019 in Review

BB Biotech reduced its Vertex Pharmaceuticals (VRTX) stake by 5.1% in Q1 2019, selling an estimated $13M and leaving 1,300,000 shares worth $239M. The position accounts for 6.01% of the portfolio, ranked #4.

BB Biotech first reported a position in VRTX in Q2 2013 and has held it in 24 quarters since. The position peaked at $264M in Q3 2018. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

BB Biotech held 1,300,000 shares of Vertex Pharmaceuticals worth $239M as of Q1 2019.
BB Biotech sold 70,445 Vertex Pharmaceuticals shares in Q1 2019, an estimated $13M.
Vertex Pharmaceuticals made up 6.01% of BB Biotech's portfolio in Q1 2019, its #4 holding.
BB Biotech first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
BB Biotech's Vertex Pharmaceuticals position peaked at $264M in Q3 2018.
737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.